文献速递临床试验与 GCP基础与转化研究

孟鲁司特作为前交叉韧带重建后潜在软骨保护性治疗(MOCHA试验):双盲、随机、安慰剂对照临床试验的研究方案

MOntelukast as a potential CHondroprotective treatment following Anterior cruciate ligament reconstruction (MOCHA Trial): study protocol for a double-blind, randomized, placebo-controlled clinical trial.
PubMed 文献 · Trials · 2022-01-31

这项多中心、随机、安慰剂对照试验将纳入30例接受初次前交叉韧带重建、年龄25-50岁且合并半月板损伤的个体,随机接受术后每日口服孟鲁司特10 mg持续6个月或安慰剂,评估其是否降低全身炎症标志物及软骨退变的生化和影像生物标志物。目前尚无延迟或预防前交叉韧带损伤后创伤性骨关节炎的治疗方法。

要点

  • 合并前交叉韧带与半月板损伤者中超过80%在10-15年内发生创伤性骨关节炎。
  • 试验纳入30例初次前交叉韧带重建、年龄25-50岁合并半月板损伤者。
  • 干预为术后每日口服孟鲁司特10 mg持续6个月,对照为安慰剂。

核心结论

  • 研究将评估术后6个月口服孟鲁司特疗程是否影响创伤性骨关节炎的多种机制;若本试验证实有效,结果可立即融入临床实践,因孟鲁司特可安全长期给药且为低成本治疗选择。

研究设计与样本

  • 多中心、随机、安慰剂对照双盲临床试验,计划纳入30例接受初次前交叉韧带重建、年龄25-50岁合并半月板损伤的个体,随机分为术后每日口服孟鲁司特10 mg持续6个月组或安慰剂组。
  • 在术前及术后1、6、12个月进行评估。
  • 试验注册于ClinicalTrials.gov NCT04572256,注册日期2020年10月1日。

关键数值与推荐

  • 术后10年患者报告结局改善,但术后数年细胞因子浓度仍升高,合并前交叉韧带与半月板损伤者中超过80%在10-15年内发生创伤性骨关节炎。
  • 将比较两组间前列腺素E2、单核细胞趋化蛋白-1和促炎细胞因子的全身浓度。
  • 将比较两组术后1个月和12个月磁共振成像上的退变改变,并以尿II型胶原分解和骨重塑生物标志物评估软骨退变早期生物标志物的降低。

临床怎么用

  • 目前尚无延迟或预防前交叉韧带损伤后创伤性骨关节炎的治疗方法。
  • 原文指出,由于前交叉韧带重建后的炎症反应比初始损伤更大且更持久,治疗可能需要在术后开始、持续一段时间并针对多种机制,方能成功改变疾病进程。
  • 原文认为,若本试验证实孟鲁司特有效,因该药可安全长期给药且为低成本治疗选择,结果可立即融入临床实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: After anterior cruciate ligament (ACL) reconstruction, patient-reported outcomes are improved 10 years post-surgery; however, cytokine concentrations remain elevated years after surgery with over 80% of those with combined ACL and meniscus injuries having posttraumatic osteoarthritis (PTOA) within 10-15 years. The purpose of this multicenter, randomized, placebo-controlled trial is to assess whether a 6-month course of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and biochemical and imaging biomarkers of cartilage degradation. METHODS: We will enroll 30 individuals undergoing primary ACL reconstruction to participate in this IRB-approved multicenter clinical trial. This trial will target those at greatest risk of a more rapid PTOA onset (age range 25-50 with concomitant meniscus injury). Patients will be randomly assigned to a group instructed to take 10 mg of montelukast daily for 6 months following ACL reconstruction or placebo. Patients will be assessed prior to surgery and 1, 6, and 12 months following surgery. To determine if montelukast alters systemic inflammation following surgery, we will compare systemic concentrations of prostaglandin E2, monocyte chemoattractant protein-1, and pro-inflammatory cytokines between groups. We will also compare degradative changes on magnetic resonance imaging (MRI) collected 1 and 12 months following surgery between groups with reductions in early biomarkers of cartilage degradation assessed with urinary biomarkers of type II collagen breakdown and bony remodeling. DISCUSSION: There is a complex interplay between the pro-inflammatory intra-articular environment, underlying bone remodeling, and progressive cartilage degradation. PTOA affects multiple tissues and appears to be more similar to rheumatoid arthritis than osteoarthritis with respect to inflammation. There is currently no treatment to delay or prevent PTOA after ACL injury. Since there is a larger and more persistent inflammatory response after ACL reconstruction than the initial insult of injury, treatment may need to be initiated after surgery, sustained over a period of time, and target multiple mechanisms in order to successfully alter the disease process. This study will assess whether a 6-month postoperative course of oral montelukast affects multiple PTOA mechanisms. Because montelukast administration can be safely sustained for long durations and offers a low-cost treatment option, should it be proven effective in the current trial, these results can be immediately incorporated into clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov NCT04572256 . Registered on October 1, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jacobs CA, Conley CEW, Kraus VB, et al. MOntelukast as a potential CHondroprotective treatment following Anterior cruciate ligament reconstruction (MOCHA Trial): study protocol for a double-blind, randomized, placebo-controlled clinical trial. Trials. 2022. PMID: 35101085. doi:10.1186/s13063-021-05982-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。